1-6 of 6
Akshanth R. Polepally
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Ravi Vij, Shaji Kunnathu Kumar, Anita D'Souza, John T Mckay, Peter M. Voorhees, Alfred Chung, Sascha Alexander Tuchman, Neha Korde, Katja Weisel, Raphael Teipel, Orlando Bueno, Zhongling Feng, Tanya S Rosenberg, Rajvineeth Kumar Pothacamury, Akshanth R Polepally, Shane Lee, Ziyi Jin, Jeremy A Ross, Aarif Ahsan, Chetasi Talati, Cesar Rodriguez
Journal: Blood
Blood (2023) 142 (Supplement 1): 3378.
https://doi.org/10.1182/blood-2023-182388
Published: 2023
Journal Articles

Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Akshanth R Polepally, Carla Biesdorf, Muhammad Erfan Uddin, Nils Boehm, Jeremy A Ross, Shaji Kunnathu Kumar, Peter M. Voorhees, Anita D'Souza, Katja Weisel, Orlando Bueno, Chetasi Talati, Rajeev M Menon
Journal: Blood
Blood (2023) 142 (Supplement 1): 6722.
https://doi.org/10.1182/blood-2023-180127
Published: 2023
Journal Articles

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Cesar Rodriguez, Katja Weisel, Rachid C. Baz, Akshanth R. Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D'Amico, Orlando F. Bueno, Leanne Lash Fleming, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 7326–7327.
https://doi.org/10.1182/blood-2022-157977
Published: 2022
Journal Articles

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Peter M. Voorhees, Anita D'Souza, Katja Weisel, David Duane Hurd, Raphael Teipel, Alfred Chung, Cesar Rodriguez, Sascha A. Tuchman, Neha Korde, Hana Safah, Orlando F. Bueno, Neil Pumford, Tanya S Rosenberg, Rajvineeth Kumar Pothacamury, Jeremy A. Ross, Akshanth R. Polepally, Shane Lee, Ziyi Jin, Chetasi Talati, Ravi Vij, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 4401–4404.
https://doi.org/10.1182/blood-2022-167008
Published: 2022
Journal Articles

A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Shaji Kumar, Anita D'Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Orlando F. Bueno, Ben Buelow, Kevin J. Freise, Susan Yue, Rajvineeth Kumar Pothacamury, Akshanth R. Polepally, Ravi Vij
Journal: Blood
Blood (2021) 138 (Supplement 1): 900.
https://doi.org/10.1182/blood-2021-150757
Published: 2021
Journal Articles

A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Akshanth R. Polepally, PhD, Monica Motwani, PhD, Yunming Mu, PhD, Zeena Salman, MPH, Sudhir Penugonda, MD MPH, Philippe Moreau, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-137037
Published: 2020